Observational studyCancer biology & medicine2026

Efficacy and safety of first-line osimertinib in Chinese patients with EGFR-mutated advanced non-small cell lung cancer: a prospective, multicenter, non-interventional study (FLOURISH).

Lisha Shen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.